Glucocorticoids in the treatment of bullous diseases

Dermatologic Therapy

Volumn 15, Issue 4, 2002, Pages 298-310

  DeHoratius, Danielle M ^a   Sperber, Brian R ^a   Werth, Victoria P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bullous diseases; Glucocorticoids; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BETAMETHASONE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CARBONATE; CLOBETASOL; CORTICOTROPIN; CORTISONE ACETATE; CYCLOPHOSPHAMIDE; DAPSONE; DEXAMETHASONE; ERGOCALCIFEROL; ETIDRONIC ACID; FLUOCINONIDE; GLUCOCORTICOID; GOLD; HYDROCHLOROTHIAZIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PREDNISONE; RISEDRONIC ACID; TETRACYCLINE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG;

ACNE; ALOPECIA; ANAPHYLAXIS; ARTHRALGIA; ATHEROSCLEROSIS; AVASCULAR NECROSIS; BLOOD TOXICITY; BONE NECROSIS; BRAIN PSEUDOTUMOR; BULLOUS SKIN DISEASE; CATARACT; DEPRESSION; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; ELECTROLYTE DISTURBANCE; ENDOCRINE DISEASE; ERYTHEMA; FATTY LIVER; FLUSHING; GASTROINTESTINAL HEMORRHAGE; GLAUCOMA; GROWTH DISORDER; HEART ARRHYTHMIA; HICCUP; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPOKALEMIC ALKALOSIS; HYPOTENSION; INTESTINE PERFORATION; MUSCULOSKELETAL DISEASE; MYOPATHY; NAUSEA; NEUROTOXICITY; NEUTROPHILIA; OSTEOPOROSIS; PANCREATITIS; PEPTIC ULCER; PSYCHOSIS; REVIEW; RISK ASSESSMENT; SEIZURE; SEPSIS; SKIN ATROPHY; SKIN DISEASE; SLEEP DISORDER; STEROID THERAPY; STRIA; TASTE DISORDER; TREATMENT INDICATION; TREATMENT OUTCOME; URTICARIA; VOMITING;

EID: 0036969023     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1529-8019.2002.01538.x     Document Type: Review

References (95)

1. Williams LC, Nesbitt LT Jr. Update on systemic glucocorticosteroids in dermatology. Dermatol Clin 2001: 19: 63-77.
2. Myles AB, Bacon PA, Daly JR. Single daily dose corticosteroid treatment. Effect on adrenal function and therapeutic efficacy in various diseases. Ann Rheum Dis 1971: 30: 149-153.
3. Huilgol SC, Black MM. Management of the immunobullous disorders. I. Pemphigoid. Clin Exp Dermatol 1995: 20: 189-201.
4. Huilgol SC, Black MM. Management of the immunobullous disorders. II. Pemphigus. Clin Exp Dermatol 1995: 20: 283-293.
5. Glied M, Rico MJ. Treatment of autoimmune blistering diseases. Dermatol Clin 1999: 17: 431-440.
6. Sabir S, Werth VP. Pulse glucocorticoids. Dermatol Clin 2000: 18: 437-446.
7. Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol 1996: 132: 1435-1439.
8. Roujeau J. Pulse glucocorticoid therapy, the big "shot" revisited. Arch Dermatol 1996: 132: 1499-1502.
9. Fine JD. Management of acquired bullous skin diseases. N Engl J Med 1995: 333: 1475-1484.
10. Weusten BL, Jacobs JW, Bijlsma JW. Corticosteroid pulse therapy in active rheumatoid arthritis. Semin Arthritis Rheum 1993: 23: 183-192.
11. Baethge BA, Lidsky MD, Goldberg JW. A study of adverse effects of high-dose intravenous (pulse) methylprednisolone therapy in patients with rheumatic disease. Ann Pharmacother 1992: 26: 316-320.
12. Arsura E, Brunner NG, Namba T, Grob D. High-dose intravenous methylprednisolone in myasthenia gravis. Arch Neurol 1985: 42: 1149-1153.
13. Pasricha JS, Khaitan BK, Raman RS, Chandra M. Dexamethasone-cyclophosphamide pulse therapy for pemphigus. Int J Dermatol 1995: 34: 875-882.
14. Oliveri RL, Sibilia G, Valentino P, et al. Pulsed methylprednisolone induces a reversible impairment of memory in patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand 1998: 97: 366-369.
15. Dhar S, Kanwar AJ. Facial flushing - a side effect of pulse therapy. Dermatology 1994: 188: 332.
16. Kanwar AJ, Kaur S, Dhar S, Ghosh S. Hiccup - a side-effect of pulse therapy. Dermatology 1993: 187: 279.
17. Bonnotte B, Chauffert B, Martin F, Lorcerie B. Side-effects of high-dose intravenous (pulse) methylprednisolone therapy cured by potassium infusion. Br J Rheumatol 1998: 37: 109.
18. Werth VP. Glucocorticoids in autoimmune connective tissue diseases. Dermatol Ther 2001: 14: 134-142.
19. Sallay P, Reusz G, Tulassay T. Esophageal perforation after pulse methylprednisolone treatment for acute kidney-graft rejection. Transplant Proc 1994: 26: 98.
20. Candelas G, Jover JA, Fernandez B, et al. Perforation of the sigmoid colon in a rheumatoid arthritis patient treated with methylprednisolone pulses. Scand J Rheumatol 1998: 27: 152-153.
21. White KP, Driscoll MS, Rothe MJ, Grant-Kels JM. Severe adverse cardiovascular effects of pulse steroid therapy: is continuous cardiac monitoring necessary?. J Am Acad Dermatol 1994: 30: 768-773.
22. Werth VP. Management and treatment with systemic glucocorticoids. Adv Dermatol 1993: 8: 81-101.
23. Gilbertson EO, Spellman MC, Piacquadio DJ, Mulford MI. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations. J Am Acad Dermatol 1998: 38: 318-321.
24. Graber AL, Ney RL, Nicholson WE. Natural history of pituitary-adrenal recovery following long-term suppression with corticosteroids. J Clin Endocrinol Metab 1965: 25: 11-16.
25. Salem M, Tainsh RE Jr, Bromberg J, et al. Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. Ann Surg 1994: 219: 416-425.
26. Auerbach R, Bystryn JC. Plasmapheresis and immunosuppressive therapy. Effect on levels of intercellular antibodies in pemphigus vulgaris. Arch Dermatol 1979: 115: 728-730.
27. Swanson DL, Dahl MV. Pemphigus vulgaris and plasma exchange: clinical and serologic studies. J Am Acad Dermatol 1981: 4: 325-328.
28. Guillaume JC, Roujeau JC, Morel P, et al. Controlled study of plasma exchange in pemphigus. Arch Dermatol 1988: 124: 1659-1663.
29. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001: 44: 1496-1503.
30. Baxter JD. Advances in glucocorticoid therapy. Adv Intern Med 2000: 45: 317-349.
31. Vittorio CC, Werth VP. Preventive techniques to limit glucocorticoid-induced side effects. Adv Dermatol 2000: 16: 273-297.
32. Walker BR, Phillips DI, Noon JP, et al. Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension 1998: 31: 891-895.
33. Krakoff LR. Glucocorticoid excess syndromes causing hypertension. Cardiol Clin 1988: 6: 537-545.
34. David DS, Grieco MH, Cushman P Jr. Adrenal glucocorticoids after twenty years. A review of their clinically relevant consequences. J Chronic Dis 1970: 22: 637-711.
35. Colao A, Pivonello R, Spiezia S, et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999: 84: 2664-2672.
36. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998: 339: 1349-1357.
37. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994: 344: 1383-1389.
38. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996: 335: 1001-1009.
39. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996: 335: 453-461.
40. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998: 280: 605-613.
41. Lane NE, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin N Am 1998: 27: 465-483.
42. Werth VP. Systemic glucocorticoids and the skin: dermatologists can prevent steroid-induced osteoporosis. Med Surg Dermatol 1996: 3: 343-346.
43. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998: 339: 292-299.
44. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis, pathogenesis and management. Ann Intern Med 1990: 112: 352-364.
45. Reid IR, Heap SW. Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med 1990: 150: 2545-2548.
46. McKenzie R, Reynolds JC, O'Fallon A, et al. Decreased bone mineral density during low dose glucocorticoid administration in a randomized, placebo controlled trial. J Rheumatol 2000: 27: 2222-2226.
47. Rizzato G, Montemurro L. Reversibility of exogenous corticosteroid-induced bone loss. Eur Respir J 1993: 6: 116-119.
48. Pocock NA, Eisman JA, Dunstan CR, et al. Recovery from steroid-induced osteoporosis. Ann Intern Med 1987: 107: 319-323.
49. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001: 44: 1496-1503.
50. Reid DM, Hughes RA, Laan RF. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000: 15: 1006-1013.
51. Reid IR. Glucocorticoid-induced osteoporosis. Best Practice Res Clin Endocrinol Metab 2000: 14: 279-298.
52. Lane NE. An update on glucocorticoid-induced osteoporosis. Rheum Dis Clin N Am 2001: 27: 235-253.
53. Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 1999: 130: 431-439.
54. Cranney A, Welch V, Adachi JD. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000: CD001983.
55. Pun KK, Chan LW. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 1989: 11: 205-209.
56. LaPier TK. Glucocorticoid- induced muscle atrophy. The role of exercise in treatment and prevention. J Cardiopulm Rehab 1997: 17: 76-84.
57. Griffin D, Fairman N, Coursin D, et al. Acute myopathy during treatment of status asthmaticus with corticosteroids and steroidal muscle relaxants. Chest 1992: 102: 510-514.
58. Behbehani NA, Al-Mane F, D'yachkova Y, et al. Myopathy following mechanical ventilation for acute severe asthma: the role of muscle relaxants and corticosteroids. Chest 1999: 115: 1627-1631.
59. Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin 1992: 10: 505-512.
60. Limaye SR, Pillai S, Tina LU. Relationship of steroid dose to degree of posterior subcapsular cataracts in nephrotic syndrome. Ann Ophthalmol 1988: 20: 225-227.
61. MacGregor RR, Sheagren JN, Lipsett MB, Wolff SM. Alternate-day prednisone therapy. Evaluation of delayed hypersensitivity responses, control of disease and steroid side effects. N Engl J Med 1969: 280: 1427-1431.
62. Weinreb RN, Bloom E, Baxter JD, et al. Detection of glucocorticoid receptors in cultured human trabecular cells. Invest Ophthalmol Vis Sci 1981: 21: 403-407.
63. Skuta GL, Morgan RK. Corticosteroid-induced glaucoma. In: Ritch R, Shields MB, Krupin T, eds. The glaucomas. St. Louis: Mosby, 1996: 1177-1188.
64. Garbe E, LeLorier J, Boivin JF, Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet 1997: 350: 979-982.
65. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal antiinflammatory drugs. Ann Intern Med 1991: 114: 735-740.
66. Hernandez-Diaz S, Rodriguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol 2001: 153: 1089-1093.
67. Runzi M, Layer P. Drug-associated pancreatitis: facts and fiction. Pancreas 1996: 13: 100-109.
68. Frick TW, Speiser DE, Bimmler D, Largiader F. Drug-induced acute pancreatitis: further criticism. Dig Dis 1993: 11: 113-132.
69. Yoshizawa Y, Ogasa S, Izaki S, Kitamura K. Corticosteroid-induced pancreatitis in patients with autoimmune bullous disease: case report and prospective study. Dermatology 1999: 198: 304-306.
70. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis 1986: 134: 355-373.
71. Dale DC, Fauci AS, Wolff SM. Alternate-day prednisone. Leukocyte kinetics and susceptibility to infections. N Engl J Med 1974: 291: 1154-1158.
72. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996: 71: 5-13.
73. Truhan AP, Ahmed AR. Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy 1989: 62: 375-391.
74. Arner P, Gunnarsson R, Blomdahl S, Groth CG. Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care 1983: 6: 23-25.
75. Hoogwerf B, Danese RD. Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin N Am 1999: 25: 489-505.
76. Nesbitt LT Jr. Minimizing complications from systemic glucocorticosteroid use. Dermatol Clin 1995: 13: 925-939.
77. Avioli LV. Glucocorticoid effects on statural growth. Br J Rheumatol 1993: 32(suppl 2): 27-30.
78. Meunier PJ, Dempster DW, Edouard C, et al. Bone histomorphometry in corticosteroid-induced osteoporosis and Cushing's syndrome. Adv Exp Med Biol 1984: 171: 191-200.
79. Wehrenberg WB, Bergman PJ, Stagg L, et al. Glucocorticoid inhibition of growth in rats: partial reversal with somatostatin antibodies. Endocrinology 1990: 127: 2705-2708.
80. Reid IR, Gluckman PD, Ibbertson HK. Insulin-like growth factor 1 and bone turnover in glucocorticoid-treated and control subjects. Clin Endocrinol 1989: 30: 347-353.
81. Butenandt O. Rheumatoid arthritis and growth retardation in children: treatment with human growth hormone. Eur J Pediatr 1979: 130: 15-28.
82. Allen DB, Goldberg BD. Stimulation of collagen synthesis and linear growth by growth hormone in glucocorticoidtreated children. Pediatrics 1992: 89: 416-421.
83. Sanchez CP, Goodman WG, Brandli D, et al. Skeletal response to recombinant human growth hormone (rhGH) in children treated with long-term corticosteroids. J Bone Miner Res 1995: 10: 2-6.
84. Storrs FJ. Intramuscular corticosteroids: a second point of view. J Am Acad Dermatol 1981: 5: 600-606.
85. Lester RS, Knowles SR, Shear NH. The risks of systemic corticosteroid use. Dermatol Clin 1998: 16: 277-288.
86. Sorensen GW, Odom RB. Axillary and inguinal striae induced by systemic absorption of a topical corticosteroid. Cutis 1976: 17: 355-357.
87. Firooz A, Tehranchi-Nia Z, Ahmed AR. Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases. Clin Exp Dermatol 1995: 20: 363-370.
88. Ledford DK. Corticosteroids in respiratory allergy: adverse effects of inhaled glucocorticoids. Immunol Allergy Clin N Am 1999: 19: 819-836.
89. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther 1972: 13: 694-698.
90. Wolkowitz OM, Reus VI, Canick J, et al. Glucocorticoid medication, memory and steroid psychosis in medical illness. Ann N Y Acad Sci 1997: 823: 81-96.
91. Bloch M, Gur E, Shalev A. Chlorpromazine prophylaxis of steroid-induced psychosis. Gen Hosp Psychiatry 1994: 16: 42-44.
92. Silva RG, Tolstunov L. Steroid-induced psychosis: report of a case. J Oral Maxillofac Surg 1995: 53: 183-186.
93. Greenberg DB, Younger J, Kaufman SD. Management of lithium in patients with cancer. Psychosomatics 1993: 34: 388-394.
94. Stiefel FC, Breitbart WS, Holland JC. Corticosteroids in cancer: neuropsychiatric complications. Cancer Invest 1989: 7: 479-491.
95. Malinow KL, Dorsch C. Tricyclic precipitation of steroid psychosis. Psychiatr Med 1984: 2: 351-354.